A Step‑by‑Step Guide to Interpreting Immunohistochemistry in Breast Cancer for Clinicians

When a new breast cancer case lands on your desk, the IHC panel often feels like a cryptic crossword. One misplaced clue can change treatment direction, and that pressure is real. Over the years I’ve watched residents stare at a slide, then light up when the pattern clicks. This guide is meant to turn that “aha” moment into a reliable routine, so you can trust the stains as much as the history you took.

Why IHC Matters in Breast Cancer

Immunohistochemistry (IHC) is the bridge between what the microscope shows and what the oncologist needs to prescribe. Hormone‑receptor status (ER, PR) and HER2 expression dictate whether a patient gets endocrine therapy, HER2‑targeted drugs, or chemotherapy alone. A single false‑negative or false‑positive can send a patient down the wrong therapeutic road, with cost, side effects, and outcomes to pay.

Step 1 – Verify the Pre‑analytical Factors

Before you even look at the stain, ask three quick questions:

1. Was the tissue fixed properly? Formalin fixation for 6‑48 hours is the sweet spot. Under‑fixation can weaken antigen detection; over‑fixation can mask it.
2. Is the block the right size? A thin, well‑oriented piece gives a clean slide. Thick or folded tissue creates uneven staining.
3. Was the slide stored correctly? Slides left at room temperature for weeks may lose antigenicity.

If any of these are off, the stain may be unreliable, and you should request a repeat.

Step 2 – Check the Controls

Every IHC run includes a positive control (tissue known to express the target) and a negative control (no primary antibody). Look at the control strip on the same slide:

• Positive control should be strongly positive – bright brown (or whatever chromogen you use) in the expected cellular compartment.
• Negative control should be blank – any staining there suggests background or reagent contamination.

If controls fail, the whole batch is suspect, regardless of what the tumor looks like.

Step 3 – Identify the Cellular Compartment

Different markers live in different parts of the cell:

• ER and PR: nuclear staining.
• HER2: membranous staining (the cell surface).
• Ki‑67: nuclear, indicating proliferation.

A common mistake is to count cytoplasmic staining for ER as positive – it is not. Keep your eyes on the right compartment, and you’ll avoid a lot of false calls.

Step 4 – Apply the Scoring System

Estrogen and Progesterone Receptors (ER/PR)

The guideline is simple:

• Positive if ≥1 % of tumor nuclei show any intensity of staining.
• Negative if <1 % of nuclei are stained.

In practice, I count a few high‑power fields (HPFs) and estimate the percentage. If you’re unsure, err on the side of “positive” – endocrine therapy is generally well tolerated and can be life‑saving.

HER2

HER2 scoring is a bit more nuanced because it guides targeted therapy:

When you see a 2+, order a fluorescence in‑situ hybridization (FISH) test. It will tell you if the HER2 gene is truly amplified.

Ki‑67

Ki‑67 is a proliferation marker. The cut‑off varies, but many labs use 20 % as a practical threshold:

• Low (<20 %): suggests a slower‑growing tumor, often hormone‑responsive.
• High (≥20 %): indicates a more aggressive tumor, may sway you toward chemotherapy.

Count the hottest spot (“hot spot”) and report the percentage of positive nuclei.

Step 5 – Note the Staining Intensity

For ER and PR, intensity (weak, moderate, strong) is less critical than the percentage, but it can help when the percentage hovers near the 1 % line. A strong, uniform stain in 2 % of cells is more convincing than a weak, patchy stain in 5 %.

Step 6 – Document the Findings Clearly

Your report should read like a short story, not a code:

“ER: 85 % of tumor nuclei show strong nuclear staining (positive).
PR: 70 % of nuclei with moderate staining (positive).
HER2: 3+ strong complete membranous staining in 60 % of cells (positive).
Ki‑67: 25 % of nuclei positive in hot spot (high proliferation).”

Avoid ambiguous language like “likely positive” unless you truly have an equivocal case. Clarity helps the oncologist plan without second‑guessing.

Step 7 – Communicate When Something Looks Off

If the pattern doesn’t fit the clinical picture—say a triple‑negative tumor with a bright HER2 3+—pause. Double‑check the slide, the controls, and the patient’s prior pathology. Sometimes a labeling error or a mixed‑tumor sample sneaks in. A quick phone call to the lab can prevent a costly mistake.

Step 8 – Keep Learning the Updates

Guidelines evolve. The ASCO/CAP updates for HER2 in 2022 refined the 2+ category and introduced a “dual‑probe” FISH approach. Keep a bookmarked copy of the latest recommendations on The Pathology Perspective site; I update the page after every major change.

A Personal Note

I still remember my first breast cancer case as a fellow. The resident stared at a HER2 2+ slide, sweat beading on his forehead. I walked over, pointed out the subtle incomplete membrane staining, and said, “When in doubt, let the DNA speak.” We ordered FISH, found no amplification, and the patient avoided an unnecessary HER2 drug. That moment taught me that IHC is a tool, not a verdict, and that a calm, systematic walk‑through saves lives.

Quick Checklist for the Busy Clinician

• Verify fixation time (6‑48 h) and slide freshness.
• Confirm positive and negative controls are appropriate.
• Look for nuclear (ER/PR/Ki‑67) vs membranous (HER2) staining.
• Apply the percentage thresholds: ≥1 % for ER/PR, >10 % for HER2 scoring.
• Use the 0‑1‑2+‑3+ HER2 scale; send equivocal (2+) for FISH.
• Report Ki‑67 hot‑spot percentage; note low vs high.
• Write a clear, concise report; flag any discordant findings.

By following these steps, you turn a complex panel into a reliable decision‑making tool. The next time you receive an IHC report, you’ll know exactly what each number means and how it fits into the bigger treatment picture.